期刊文献+

电感耦合等离子体质谱法测定索非布韦原料药锡的残留量 被引量:1

Assay Determination of Tin Residue in Sofosbuvir by ICP-MS
下载PDF
导出
摘要 建立电感耦合等离子体质谱法测定索非布韦原料药锡的残留量,并进行方法学考察。将样品置于微波罐中,加入9 m L硝酸,150℃预消解5 min,再用微波消解仪快速消解,消解结束后将消解液置于150℃赶酸仪上赶酸至1 m L以下,将消解液转移至10 m L塑料量瓶中,用纯水定容至刻度,量取溶液,注入电感耦合等离子体质谱仪(ICP-MS)测定。结果表明,锡在0 ug/L^20 ug/L浓度范围内与离子强度呈良好的线性关系(r=0.999 8);精密称取本品7份,检出锡的含量,相对标准偏差(RSD)(n=7)为6.52%,重复性良好;锡对照品溶液重复进样6次,RSD(n=6)为4.05%,进样精密度良好;样品的加样回收率在97%~103%范围内,表明该测定方法的准确度良好。该方法简便、快速、重复性好、精密度好、准确度好。 To establish an ICP-MS method for assay determination of tin residue in Sofosbuvir. The methodological study was also conducted. The sample was placed in a microwave tank,9 m L of nitric acid was added,andthe digestion was carried out at 150°C for 5 minutes. The digestion solution was quickly digested with a micro-wave digestion. After digestion,the digestion solution was transferred to 1 m L or less at 150°C,10 m L plastic mea-suring bottle,constant volume with pure water. The solution was injected into the ICP-MS determination. The linear range of tin is 0 ug/L ~20 ug/L;reproducibility is good when the RSD of 7 batches samples is 6.52 %. The in-jection precision is good with RSD 4.05 %. The sample recovery rate is in the range of 97 % ~103%. The method is simple,and has good reproducibility,accuracy and precision,which is suitable for the assay determinationof tin residue in Sofosbuvir.
作者 严宾
出处 《江苏工程职业技术学院学报》 2017年第3期24-26,共3页 Journal of Jiangsu College of Engineering and Technology
关键词 索非布韦 锡的残留量 电感耦合等离子体质谱法 Sofosbuvir tin residue ICP-MS
  • 相关文献

参考文献3

二级参考文献62

  • 1Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wildtype and resistant genotype 1 hepatitis C virus replication in patients[J]. Hepatology,2007,46(3):631-639.
  • 2Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J]. Gastroenterology, 2007,132(4): 1270-1278.
  • 3Anonymous. Combination therapy with HCV protease inhibitor boceprevir produces a high rate of early virological response in genotype 1 hepatitis C patients[EB/OL].[2008- 01-09 ]. http ://www. hivandh epatitis. com/hep_c/news/2007/102307_a.html.
  • 4Baker R. Experimental Roche polymerase inhibitor R1626 shows robust synergistic effect in combination with pegylated interferon with or without ribavirin[C/OL]//58th Annual Meeting of the American Association for the Study of Liver Diseases,Boston,USA,November 2-6,2007. [2008-01-07].http : //www. hivandhepatitis. com/2007icr/aasld/docs/110607_b. html.
  • 5Kaita K, Yoshida E, Kunimoto D, et al. Phase Ⅱ proof of concept study of celgosivir in combination with peginterferon alf a-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients[C/OL]//42nd Meeting of the European Association for the Study of Liver Diseases,Barcelona, Spain, April 11-15, 2007.[2008 -01-09]. http://www.natap.org/2007/ EASL/EASL_61.htm.
  • 6Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection [J]. Lancet Infect Dis,2005,5(9): 558-567.
  • 7Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology,2005,42(4):962-973.
  • 8Nakano T, Lu L, He Y, et al. Population genetic history of hepatitis C virus lb infection in China[J]. J Gen Virol,2006, 87(Pt 1):73-82.
  • 9Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update[J]. Ann Pharmacother,2006,40(1): 74-82.
  • 10Kemmer N, Neff GW.Managing chronic hepatitis C in the diffficuh-to-treat patient[J]. Liver Int,2007,27 (10):1297- 1310.

共引文献22

同被引文献12

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部